Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Clearmind Medicine Inc. Common Shares (CMND)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: CMND (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -49.25% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.78M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -1.31 | 52 Weeks Range 0.80 - 2.30 | Updated Date 06/29/2025 |
52 Weeks Range 0.80 - 2.30 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.23% | Return on Equity (TTM) -139.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 168145 | Price to Sales(TTM) - |
Enterprise Value 168145 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.79 | Shares Outstanding 5379440 | Shares Floating 4864790 |
Shares Outstanding 5379440 | Shares Floating 4864790 | ||
Percent Insiders 2.8 | Percent Institutions 11.19 |
Upturn AI SWOT
Clearmind Medicine Inc. Common Shares
Company Overview
History and Background
Clearmind Medicine Inc. is a biotech company focused on developing novel psychedelic-derived therapeutics. Founded in 2019, it is dedicated to discovering, developing, and commercializing novel psychedelic-derived compounds for treating various health problems. It has focused on developing and testing drugs based on MEAI.
Core Business Areas
- Pharmaceutical Development: Researching and developing novel psychedelic-derived therapeutics, focusing on metabolic disorders and addiction.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
- Intellectual Property: Securing patents for its novel compounds and formulations.
Leadership and Structure
Clearmind Medicine Inc. has a board of directors and an executive management team overseeing its operations. The company structure is typical for a biotech company, with departments dedicated to research, development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- MEAI-Based Therapies: Clearmind's primary focus is on developing therapies based on MEAI, a novel psychedelic-derived compound. These therapies are targeted towards treating metabolic disorders, such as obesity and type 2 diabetes, as well as addiction. Market share is currently minimal as the therapies are in the clinical trial phase. Competitors include companies developing other psychedelic-assisted therapies for similar indications, such as COMPASS Pathways (CMPS) and Cybin Inc (CYBN).
Market Dynamics
Industry Overview
The psychedelic therapeutics industry is rapidly growing, driven by increasing awareness of the potential benefits of psychedelics for mental health and other conditions. There is growing acceptance that psychedelics are safe and can provide benefits to patients. The market is characterized by a mix of publicly traded and private companies. Research shows that this market is still in its early stages, but has significant growth potential.
Positioning
Clearmind Medicine Inc. is positioned as an innovator in the psychedelic therapeutics space, focusing on metabolic disorders and addiction. Its competitive advantage lies in its novel MEAI-based therapies and intellectual property portfolio.
Total Addressable Market (TAM)
The total addressable market for psychedelic therapeutics is estimated to reach billions of dollars. Clearmind Medicine Inc. is positioned to capture a portion of this market through its novel MEAI-based therapies. As the company is focusing on a specific indication this should reduce the number of competitors significantly.
Upturn SWOT Analysis
Strengths
- Novel MEAI-based therapies
- Intellectual property portfolio
- Focus on metabolic disorders and addiction
- Early mover advantage in a niche market
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Lack of established commercial infrastructure
- High regulatory hurdles
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new indications
- Positive clinical trial results
- Increased acceptance of psychedelic therapeutics
Threats
- Competition from larger pharmaceutical companies
- Regulatory setbacks
- Clinical trial failures
- Negative public perception of psychedelics
Competitors and Market Share
Key Competitors
- CMPS
- CYBN
- GHRS
Competitive Landscape
Clearmind Medicine Inc. faces intense competition from larger, more established pharmaceutical companies. Its success depends on its ability to differentiate its MEAI-based therapies and secure regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Clearmind is an early-stage company and therefore historical growth will need to be assessed as it conducts its research and development trials.
Future Projections: Future growth is dependent on the success of clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing MEAI-based therapies through clinical trials and securing patents.
Summary
Clearmind Medicine Inc. is a young biotech company with novel MEAI-based therapies targeting metabolic disorders and addiction. Its strengths lie in its unique approach and intellectual property. However, it faces challenges related to funding, regulatory hurdles, and competition. The company's future hinges on the success of its clinical trials and strategic partnerships. It is a high-risk, high-reward investment at this early stage.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- Public filings
- Industry reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in early-stage biotech companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clearmind Medicine Inc. Common Shares
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2021-08-16 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | |
Full time employees - | |||
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. The company develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post traumatic stress disorder and other health conditions. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is based in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.